CONFIDENTIAL INFORMATION OMITTED AND FILED Sample Clauses

CONFIDENTIAL INFORMATION OMITTED AND FILED. SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION and the TBD Title will be ready and available for purchase by retailers in U.S. English on or before CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, and on or before CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION in the following languages: CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION / BRILLIANT DIGITAL ENTERTAINMENT, INC. CONFIDENTIAL 1.7. DIALOGUE AND TEXT: CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
AutoNDA by SimpleDocs
CONFIDENTIAL INFORMATION OMITTED AND FILED. SEPARATELY WITH THE SEC WITH A REQUEST FOR CONFIDENTIAL TREATMENT BY INTER PARFUMS, INC. NO. 10.111:12.
CONFIDENTIAL INFORMATION OMITTED AND FILED. Separately with the Commission. Omitted Portions Indicated by [**]. SCHEDULE H CHANGE CONTROL PROCEDURES -------------------------
CONFIDENTIAL INFORMATION OMITTED AND FILED. SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS (*) DENOTE SUCH OMISSIONS. [XXXX LETTERHEAD] SCHEDULE I FOR PPI (Project code 110-02) Primary Contact - - Xxxx Xxxxxx & Xxxx Xxxxxxx, Ph.D. ph: 000-000-0000 Praecis Pharmaceuticals Inc. fax: 000-000-0000 0 Xxxxxxxxx Xxxxxx Xxxxxxxxx, XX 00000-0000 Product Description -- PPI-149 Depot powder filled in a vial; used to treat prostate cancer. Safety - - Respirators must be worn by all personnel entering the weighing and filling area. Storage - - Store the bulk drug substance and finished product at controlled room temperature. NOTE: The finished product will be stored for 60 days free of charge from date of XXXX release, after which PPI will accrue a storage fee of $125/month/pallet (or any quantity thereunder). ------------------------------------------------------------------------------- Raw Material & Components ------------------------------------------------------------------------------- Item Test Storage Supplied by XXXX P/N ------------------------------------------------------------------------------- XXX-000-*** X XX XXXXXX 0000-000 ------------------------------------------------------------------------------- SGD molded 3 mL x 20 mm Type I vial XXXX 2249-928 ------------------------------------------------------------------------------- West 20 mm 4432/50 stopper XXXX 2134-321 ------------------------------------------------------------------------------- West 20 mm aluminum tear-off seal XXXX 2197-321 ------------------------------------------------------------------------------- NOTE: XXXX will store any remaining bulk drug substance for 30 days after the fill date (unless other runs are scheduled) at which time all the inventory will be sent back to CLIENT, F.O.B. Bloomington ------------------------------------------------------------------------------- CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS (*) DENOTE SUCH OMISSIONS. Filling - *** Approximately 5 lines omitted *** Chemistry/Microbiology *** NOTE: *** *** Approximately 23 lines omitted *** Inspection - - *** Labeling - - *** Approximately 4 lines omitted *** Packaging - - *** Approximately 4 lines omitted *** Shipping- - Shipments are F.O.B. Bloomington. Disposal - - *** Contacts at CPS - Scientific Affairs Manager Xxxx Xxxxxxxxxx Materials Manager Xxxxxx Xxxxxx Quality Assurance Manager Xxxxxxxx Xxxxx Documentation provided by CPS -

Related to CONFIDENTIAL INFORMATION OMITTED AND FILED

  • CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION LICENSE AGREEMENT PAGE 5

  • CONFIDENTIAL PORTION OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 2.2 [**]

  • Certain Information The Company agrees to provide Holder at any time and from time to time with such information as Holder may reasonably request for purposes of Holder’s compliance with regulatory, accounting and reporting requirements applicable to Holder.

  • Access to Confidential Information Executive acknowledges that the special relationship of trust and confidence between him, the Company, and its clients and customers creates a high risk and opportunity for Executive to misappropriate the relationship and goodwill existing between the Company and its clients and customers. Executive further acknowledges and agrees that it is fair and reasonable for the Company to take steps to protect itself from the risk of such misappropriation. Executive further acknowledges that, at the outset of his employment with the Company and/or throughout his employment with the Company, Executive has been or will be provided with access to and informed of the Company’s Confidential Information, which will enable him to benefit from the Company’s goodwill and know-how.

  • Company Creation and Use of Confidential Information The Executive understands and acknowledges that the Company has invested, and continues to invest, substantial time, money and specialized knowledge into developing its resources, creating a customer base, generating customer and potential customer lists, training its employees, and improving its product offerings in the field of financial services. The Executive understands and acknowledges that as a result of these efforts, the Company has created, and continues to use and create Confidential Information. This Confidential Information provides the Company with a competitive advantage over others in the marketplace.

  • Treatment of Confidential Information (A) Each party agrees that at all times during and after the terms of this Agreement, it shall use, handle, collect, maintain, and safeguard Confidential Information in accordance with (1) the confidentiality and non-disclosure requirements of this Agreement; (2) the GLB Act, as applicable and as it may be amended; and (3) such other Applicable Law, whether in effect now or in the future.

  • Maintenance of Confidential Information The Contractor acknowledges that in the course of its appointment hereunder the Contractor will, either directly or indirectly, have access to and be entrusted with information (whether oral, written or by inspection) relating to the Company or its respective affiliates, associates or customers (the “Confidential Information”). For the purposes of this Agreement, “Confidential Information” includes, without limitation, any and all Developments (as defined herein), trade secrets, inventions, innovations, techniques, processes, formulas, drawings, designs, products, systems, creations, improvements, documentation, data, specifications, technical reports, customer lists, supplier lists, distributor lists, distribution channels and methods, retailer lists, reseller lists, employee information, financial information, sales or marketing plans, competitive analysis reports and any other thing or information whatsoever, whether copyrightable or uncopyrightable or patentable or unpatentable. The Contractor acknowledges that the Confidential Information constitutes a proprietary right, which the Company is entitled to protect. Accordingly the Contractor covenants and agrees that during the Term and thereafter until such time as all the Confidential Information becomes publicly known and made generally available through no action or inaction of the Contractor, the Contractor will keep in strict confidence the Confidential Information and shall not, without prior written consent of the Company in each instance, disclose, use or otherwise disseminate the Confidential Information, directly or indirectly, to any third party.

  • Fund Confidential Information 9.1 All information provided under this Agreement by or on behalf of a party or its agents or service providers (the “Disclosing Party”) to the other party (the “Receiving Party”) regarding the Disclosing Party’s business and operations shall be treated as confidential (“Confidential Information”). Confidential Information shall include, without limitation, “Customer Information” as defined in Section 9.2 below. All Confidential Information provided under this Agreement by the Disclosing Party shall be used, including, without limitation, disclosure to third parties, by the Receiving Party, or its agents or service providers, solely for the purpose of performing or receiving the services and discharging the Receiving Party’s other obligations under the Agreement or managing the business of the Receiving Party and its Affiliates, including, without limitation, financial and operational management and reporting, risk management, legal and regulatory compliance and client service management. The foregoing shall not be applicable to any information (a) that is publicly available when provided or thereafter becomes publicly available, other than through a breach of this Agreement, (b) that is independently derived by the Receiving Party without the use of any information provided by the Disclosing Party in connection with this Agreement, (c) that is disclosed to comply with any legal or regulatory proceeding, investigation, audit, examination, subpoena, civil investigative demand or other similar process, (d) that is disclosed as required by operation of law or regulation; or (e) where the party seeking to disclose has received the prior written consent of the Disclosing Party providing the information. A Receiving Party shall protect Confidential Information of a Disclosing Party at least to the same degree as the Receiving Party protects its own

  • Treatment of Certain Information; Confidentiality Each of the Administrative Agent, the Lenders and the L/C Issuer agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its and its Affiliates’ respective partners, directors, officers, employees, agents, trustees, advisors and representatives (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority purporting to have jurisdiction over it (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) to any other party hereto, (e) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section, to (i) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement or any Eligible Assignee invited to be a Lender pursuant to Section 2.15(c) or (ii) any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to the Borrower and its obligations, (g) with the consent of the Borrower or (h) to the extent such Information (i) becomes publicly available other than as a result of a breach of this Section or (ii) becomes available to the Administrative Agent, any Lender, the L/C Issuer or any of their respective Affiliates on a nonconfidential basis from a source other than the Borrower.

  • Treatment of Certain Confidential Information 70 18.1. Sharing of Information with Section 20 Subsidiary. .................................70 18.2. Confidentiality. ...................................................................70 18.3. Prior Notification. ................................................................71 18.4. Other. .............................................................................71 19.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!